bluebird bio names CSO
This article was originally published in Scrip
Executive Summary
Cambridge, Massachusetts-based bluebird bio, a clinical-stage company developing gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, has named Dr Philip Gregory chief scientific officer and a member of the leadership team.